Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01842035 · ClinicalTrials.gov registry record · NA
Heart Rate Response to Regadenoson and Sudden Cardiac Death
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT01842035 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 90 participants.
The verdict
NCT01842035, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.
Interventions
- DRUG regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-02 |
| Est. Completion | 2022-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01842035
The ClinicalTrials.gov registry entry for NCT01842035 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which regadenoson is the first listed.
NCT01842035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01842035 about?
NCT01842035 is a clinical study titled "Heart Rate Response to Regadenoson and Sudden Cardiac Death". The purpose of this study is to determine whether a blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.
What is the current status of trial NCT01842035?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2013-02. Estimated completion is 2022-07.
What interventions are being tested in trial NCT01842035?
The interventions under investigation include: regadenoson (DRUG).
Who is sponsoring clinical trial NCT01842035?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.